Overexpression of fibroblast growth factor receptor 3 (FGFR3) has been shown to drive oncogenesis in a subset of patients with multiple myeloma. However, epithelial cancers — such as bladder ...

FGFR3 is the most frequently altered gene in ... "For the last thirty years, I have dedicated my career to helping patients with bladder cancer as a urologic oncologist, a principal investigator ...

NDAQ:TYRA) Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302) ...

intermediate risk non-muscle invasive bladder cancer (IR NMIBC). The investigational drug TYRA-300 is a selective inhibitor designed specifically to target FGFR3 mutations, which are commonly ...

Johnson & Johnson's Balversa has become the first drug approved in the EU to treat adults with advanced urothelial carcinoma (mUC) with FGFR3 genetic ... common form of bladder cancer.

Tyra Biosciences, Inc. (NASDAQ: TYRA) shares decreased in price Friday. The Carlsbad, Calif.-based Tyra, a clinical-stage biotechnology company focused on developing next-generation precision ...